Skip to main content
SpringerLink
Log in

Medication Overuse Headache

Kopfschmerzen durch Übergebrauch von Schmerz- und Migränemitteln

  • Zertifizierte Fortbildung
  • Kopfschmerz bei Medikamentenübergebrauch
  • Published:
Schmerzmedizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Der Kopfschmerz durch Übergebrauch von Akutmedikation ist ein wesentlicher Faktor bei der Chronifizierung von Kopfschmerzattacken.

© Liderina / Getty Images / iStock

Abb. 1

Literatur

  1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders ICHD-3, 3rd edition. Cephalalgia 2018;38(1):1-211

  2. Bahra A, Walsh M, Menon S, et al. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003;43:179-90

  3. Bigal ME et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48(8):1157-68

  4. Dubowchik GM et al. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. J Med Chem 2020;63(13):6600-23

  5. de Vries T et al. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020:107528.

  6. Westergaard ML et al. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia 2014;34(6):409-25

  7. Westergaard ML et al. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain 2014;155(10):2005-13

  8. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004;3(8):475-83

  9. Mose LS et al. The role of personality, disability and physical activity in the development of medication-overuse headache: a prospective observational study. J Headache Pain 2018;19(1):39

  10. Hagen K et al. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag Health Studies. Pain 2012;153(1):56-61

  11. Schwedt TJ et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain 2018;19(1):38

  12. Scher AI et al. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia 2010;30(3):321-8

  13. Lipton RB et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 2015;84(7):688-95

  14. He Z et al. Metabolic syndrome in female migraine patients is associated with medication overuse headache: a clinic-based study in China. Euro J Neurol 2015;Aug;22(8):1228-34

  15. Diener HC et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 2019;18(9):891-902

  16. Fritsche G et al. Prevention of medication overuse in patients with migraine. Pain 2010;151(2):404-13

  17. Carlsen LN et al. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia 2018;38(7):1316-25

  18. Grande RB et al. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol 2011;18(1):129-37

  19. Kristoffersen ES et al. Brief intervention by general practitioners for medication-overuse headache, follow-up after 6 months: a pragmatic cluster-randomised controlled trial. J Neurol 2016;263(2):344-53

  20. Rossi Pet al. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol 2011;18(3):396-401

  21. Lagman-Bartolome AM et al. Headache Education Active-Waiting Directive: A Program to Enhance Well-Being During Long Referral Wait Times. Headache 2018;58(1):109-17

  22. Mose LS et al. Medication-overuse headache: The effect of a patient educational programme-A randomized controlled trial. Eur J Pain 2020;24(2):435-47

  23. Diener HC et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27(7):814-23

  24. Silberstein SD et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170-80

  25. Silberstein S et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009;49(8):1153-62

  26. Diener HC et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29(10):1021-7

  27. Limmroth V et al. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 2007;47(1):13-21

  28. Sarchielli P et al. Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. Eur Neuropsychopharmacol 2014;24(8):1289-97

  29. Dodick DW et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50(6):921-36.

  30. Diener HC et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30(7):804-14

  31. Aurora SK et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30(7):793-803

  32. Silberstein SD et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013;331(1-2):48-56

  33. Pijpers JA et al. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain 2019;142(5):1203-14

  34. Diener H et al. Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP Rezeptor. Ergänzung der S1-Leitlinie Therapie der Migräneattacke und Prophylaxe der Migräne. 2019 In: wwwdgnorg/leitlinien [Internet]. Berlin: Deutsche Gesellschaft für Neurologie

  35. Silberstein SD et al. The Impact of Fremanezumab on Medication Overuse in Patients with Chronic Migraine. Headache 2018;58:76-7

  36. Tepper S et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017;16(6):425-34

  37. Tepper SJ et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology 2019 May 14;92(20):e2309-e2320

  38. Detke HC et al. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018;91(24):e2211-e21

  39. Lipton RB et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020;94:e1365-e77

  40. Zeeberg P et al. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 2006;26(10):1192-8

  41. Tassorelli C et al. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia 2017;37:1115-25

  42. Jellestad PL et al. Economic benefits of treating medication-overuse headache - results from the multicenter COMOESTAS project. Cephalalgia 2018:333102418786265

  43. Bendtsen L et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia 2014;34(6):426-33

  44. Katsarava Z et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001;57:1694-8

  45. Chiang CC et al. Treatment of medication-overuse headache: A systematic review. Cephalalgia 2016;36(4):371-86

  46. Boe MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Neurology 2007;69(1):26-31

  47. Rabe K et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia 2013;33(3):202-7

  48. Cevoli S et al. Treatment of withdrawal headache in patients with medication overuse headache: a pilot study. J Headache Pain 2017;18(1):56

  49. Karadas O et al. Greater occipital nerve block in the treatment of triptan-overuse headache: A randomized comparative study. Acta Neurol Scand 2017;135(4):426-33

  50. Diener H et al. EAN guideline on the management of medication oversue headache. Europ J Neurology 2020: 27(7):1102-16

  51. Zidverc-Trajkovic JJ et al. Long-term predictors of remission in patients treated for medication-overuse headache at a specialized headache center: A prospective cohort study. Cephalalgia 2018;38(2):265-73

  52. Katsarava Z et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005;25(1):12-5

  53. Andrasik F et al. Disability in chronic migraine with medication overuse: treatment effects through 5 years. Cephalalgia 2010;30(5):610-4

  54. Rossi P et al. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia 2008;28(11):1196-200

  55. Gaul C et al. Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. J Headache Pain 2011;12(4):475-83

  56. Altieri M et al. Combined pharmacological and short-term psychodynamic psychotherapy for probable medication overuse headache: a pilot study. Cephalalgia 2009;29(3):293-9

  57. Grazzi L et al. Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up. J Headache Pain 2017;18(1):15

Download references

Author information

Authors and Affiliations

  1. Medizinische Fakultät der Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany

    Hans-Christoph Diener

  2. Migräne- u. Kopfschmerzklinik Königstein, Ölmühlweg 31, 61462, Königstein\/Taunus, Germany

    Charly Gaul

  3. Klinik und Poliklinik für Neurologie, Hufelandstraße 55, 45147, Essen, Germany

    Dagny Holle-Lee

  4. Universität Duisburg-Essen, Holbeinstrasse 10, 59423, Unna, Germany

    Zaza Katsarava

Authors
  1. Hans-Christoph Diener
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charly Gaul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dagny Holle-Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zaza Katsarava
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Christoph Diener.

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen. H-C. Diener hat Honorare für die Planung, Ausführung oder Teilnahme an klinischen Studien, Teilnahme an Advisory Boards oder Vorträge erhalten von: Alder, Allergan, Amgen, Biohaven, Böhringer Ingelheim, Electrocore, Ipsen Pharma, Lilly, Lundbeck, Medtronic, Novartis, Pfizer, TEVA und Weber & Weber. Finanzielle Unterstützung für Forschungsprojekte wurde gewährt von: Allergan, Electrocore und Pfizer. H-C. Diener ist Vorsitzender der Leitlinienkommission der DGN und Herausgeber der DGN Leitlinien. C. Gaul hat Honorare für die Beratung, Teilnahme an Advisory Boards oder Vorträge erhalten von: Allergan Pharma, Ratiopharm, Lilly, Novartis Pharma, Desitin Arzneimittel, Cerbotec, Bayer vital, Hormosan Pharma, Grünenthal, Reckitt Benckiser und TEVA. Er ist Generalsekretär der DMKG. Er besitzt keine Aktien oder Anteile pharmazeutischer Unternehmen. D. Holle-Lee hat Honorare für die Planung, Ausführung oder Teilnahme an klinischen Studien, Teilnahme an Advisory Boards oder Vorträge erhalten von: Alder, Allergan, Amgen, Lilly, Novartis, Sanofi, TEVA. Prof. Dagny Holle-Lee besitzt keine Aktien oder Anteile von Pharmafirmen. Z. Katsarava erhielt Zuwendungen von Allergan, Novartis, TEVA, Lilly, Böhringer Ingelheim, Daiichi-Sankyo, Bayer und Merck.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Dieser Beitrag wurde zuerst in InFo Neurologie & Psychiatrie 2020; 22(9):40-50 veröffentlicht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Diener, HC., Gaul, C., Holle-Lee, D. et al. Kopfschmerzen durch Übergebrauch von Schmerz- und Migränemitteln. Schmerzmed. 37, 18–29 (2021). https://doi.org/10.1007/s00940-020-3020-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00940-020-3020-2

Search

Navigation